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Abstract  
 
Scaffold-based analogs of cinnamic acid benzyl amide (CABA) exhibit pleiotropic effects in cancer cells, and 
their exact molecular mechanism of action is under investigation. The present study is part of our systemic 
analysis of interactions of CABA analogs with their molecular targets. These compounds were shown to 
inhibit Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) and JAK2/signal 
transducer and activator of transcription 5 (STAT5) signaling and thus are attractive scaffolds for anticancer 
drug design. To identify the potential mechanisms of action of this class of compounds, direct interactions of 
the selected CABA analogs with JAK2 kinase were examined. Inhibition of JAK2 enzymatic activity was 
assessed, and molecular modeling studies of selected compounds—(E)-2-cyano-N-[(S)-1-phenylethyl]-3-
(pyridin-2-yl)acrylamide (WP1065), (E)-2-cyano-N-[(S)-1-phenylbutyl]-3-(3-bromopyridin-2-yl)acrylamide 
(WP1130), and (E)-2-cyano-N-[(S)-1,4-diphenylbutyl]-3-(3-bromopyridin-2-yl)acrylamide (WP1702)—in 
the JAK2 kinase domain were used to support interpretation of the experimental data. Our results indicated 
that the tested CABA analogs are nonclassical inhibitors of activated (phosphorylated) JAK2, although 
markedly weaker than clinically tested ATP-competitive JAK2 inhibitors. Relatively small structural changes 
in the studied compounds affected interactions with JAK2, and their mode of action ranged from allosteric-
noncompetitive to bisubstrate competitive. These results demonstrated that direct inhibition of JAK2 
enzymatic activity by the WP1065 (half-maximal inhibitory concentration [IC50] = 14.8 μM), WP1130 (IC50 
= 3.8 μM), and WP1702 (IC50 = 2.9 μM) potentially contributes, albeit minimally, to suppression of the 
JAK2/STAT signaling pathways in cancer cells and that additional specific structural modifications may 
amplify JAK2-inhibitory effects. 
 
 
Keywords: bisubstrate-competitive, CABA, cinnamic acid, inhibitor, JAK2, molecular modeling, 
noncompetitive, STAT3, STAT5, WP1065, WP1130, WP1702.  
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INTRODUCTION 
 
Janus kinases (JAKs) are important regulators of the cytokine- and growth factor-induced JAK/signal 
transducer and activator of transcription (STAT) signaling pathways. Ligand binding to transmembrane 
receptors stimulates autophosphorylation of JAKs, which then phosphorylate STATs. Activated STATs 
dimerize, translocate to the nucleus, and turn on expression of genes responsible for cell proliferation, 
survival, differentiation, and apoptosis inhibition [1]. JAK2 has appeared to be an attractive target for 
downregulation of signaling by the JAK2/STAT pathways, and several therapeutically promising novel JAK2 
inhibitors are under clinical investigation [2]. 
Priebe and co-workers designed and synthesized a novel class of inhibitors of the JAK2/STAT 
signaling pathways [3-5] using a scaffold of natural compounds structurally related to cinnamic acid benzyl 
amide (CABA) (Fig. 1). Derivatives of cinnamic acid are important constituents of natural products (e.g., 
propolis, fruits, vegetables, herbs) and exert many biological activities (thoroughly reviewed in [6]). Their 
chemopreventive, antiproliferative, antineoplastic, and antimetastatic properties are among the most studied 
of these activities. These newly designed CABA inhibitors displayed markedly increased anticancer activity 
in a wide range of in vitro and in vivo tumor models [7-21]. In view of their well-recognized biological 
activity, systematic assessment of all potential mechanisms of action was important. CABA analogs’ ability 
to block the JAK2/STAT3 and JAK2/STAT5 pathways is clearly a result of multifactorial effects rather than 
exclusively direct inhibition of JAK2, STAT3, or STAT5 [22-26]. In addition, certain CABA derivatives may 
interact with targets outside the JAK/STAT pathways as exemplified by the CABA derivative WP1609, 
which inhibits the activity of the atypical protein kinase Rio1 [27]. 
To determine the possible contribution of direct JAK2 inhibition to the observed suppression of the 
JAK2/STAT signaling pathways by CABA analogs, we assessed direct effects of these compounds (Fig. 1) 
on JAK2’s enzymatic activity. We performed studies of in vitro inhibition of the recombinant JAK2 kinase 
domain by CABA analogs, which demonstrated that six CABA derivatives—WP1065, WP1174, WP1130, 
WP1682, WP1702, and WP1703—inhibited JAK2-catalyzed phosphorylation of the STAT5 peptide 
substrate at low micromolar levels (half-maximal inhibitory concentration [IC50] range, 2.9-22.1 μM). This 
indicated that these compounds are relatively weak JAK2 inhibitors. Furthermore, results of molecular 
modeling of interactions of selected CABA analogs with the JAK2 kinase domain pointed to ligand-specific 
mechanisms of binding. Direct but weak inhibition of JAK2 phosphorylation activity may contribute, albeit 
minimally, to the overall effects of CABA derivatives on the JAK2/STAT3 and JAK2/STAT5 signaling 
pathways. 
 
 
 
MATERIALS AND METHODS  
 
Expression of the JAK2 Kinase Domain in a Baculoviral System  
 
A cDNA encoding JAK2 (clone number 6838318; Mammalian Gene Collection EMM1002-
7498663) was purchased from Open Biosystems (Huntsville, Alabama, USA). A kinase domain-coding 
sequence (nucleotides 2410-3399, amino acids 804-1132) was amplified via polymerase chain reaction using 
the primers 5'-GATCTTAACAGCCTGTTTACTCCAG-3' and 5'-
TCACGCAGCTATACTGTCCCGGATTTG-3'. A 1-kb fragment of the JAK2 coding sequence was 
subcloned into the transfer plasmid pIEx-2 (Novagen, Darmstadt, Germany) in a frame with glutathione S-
transferase–, S-, and hexahistidine-tag sequences. Subsequently, the whole cassette was subcloned into a 
pFastBac HT plasmid to introduce it into bacmid DNA via site-specific transposition in the Escherichia coli 
DH10Bac strain (Invitrogen, Carlsbad, California, USA). Sf21 insect cells were used for transfection and 
generation of a recombinant baculovirus and for baculovirus amplification and titration. Infection of HF 
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insect cells was the final step in the production of a recombinant JAK2 protein. All of these procedures were 
carried out according to the manufacturer’s instructions (Invitrogen). 
 
Protein Purification  
 
HF cells were lysed via freeze-thaw cycles in a lysis buffer (50 mM Tris-HCl, pH 8.0, 0.05 M NaCl, 
1% isooctylphenoxypolyethoxyethanol [Triton X-100], 1 mM dithiothreitol [DTT], 10% glycerol) containing 
a protease inhibitor cocktail (Roche, Indianapolis, Indiana, USA). To reduce the viscosity, the lysate was 
incubated with Benzonase nuclease (2.5 U・μl-1; Novagen) for 30 minutes on ice. After adding NaCl to the 
0.5-M final concentration, the lysate was clarified (50000・g, 60 minutes, 4°C), and the supernatant was 
adsorbed onto glutathione-agarose beads (Sigma-Aldrich, St. Louis, Missouri, USA) for 2 hours at 4°C. The 
resin was washed with another buffer (50 mM Tris-HCl, pH 8.0, 0.2 M NaCl, 0.1% Triton X-100, 1 mM 
DTT, 10% glycerol). The JAK2 protein was eluted with the wash buffer containing 10 mM reduced 
glutathione (Sigma-Aldrich). Collected fractions were concentrated and dialyzed on Microcon filters 
(MWCO, 50 kDa; EMD Millipore, Billerica, Massachusetts, USA) against 25 mM Tris-Cl, pH 8.0, 0.2 M 
NaCl, 0.05% Triton X-100, 1 mM DTT, and 10% glycerol. 
To obtain preautophosphorylated JAK2, an additional step was introduced into the protein 
purification procedure. Specifically, the lysate was incubated at 4°C with 10 mM ATP (Fermentas, Vilnius, 
Lithuania), 10 mM MgCl2, 1 mM Na3VO4, and 5 mM NaF. The magnesium ions and protein phosphatase 
inhibitors were then maintained in the purification buffers. 
The influence of various types of detergents on the stability of the JAK2 kinase domain was 
analyzed. Recombinant JAK2 bound to glutathione-agarose beads was cleaved with 2.5 U thrombin protease 
(Sigma-Aldrich) for several hours at 4°C. The resulting preparations were clarified via microcentrifugation, 
and the supernatants were analyzed using polyacrylamide gel electrophoresis. The detergents used were 
Triton X-100 (BDH Chemicals, Radnor, Pennsylvania, USA), 3-(3-cholamidopropyl) dimethylammonio-1-
propanesulfonate (CHAPS; BioShop, Burlington, Ontario, Canada), polyethylene glycol 400 dodecyl ether 
(Thesit; Fluka, St. Louis, Missouri, USA), polyoxyethylene (20) sorbitan monolaurate (Tween-20; BioShop), 
n-dodecyl β-D-maltoside (DDM; Sigma-Aldrich), and polyoxyethylene lauryl ether (Brij 35; BDH 
Chemicals). 
Protein preparations were analyzed using 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE), and the protein concentration was determined using a protein assay kit (Bio-Rad, 
Hercules, California, USA) with bovine serum albumin as a standard. Western blot analysis was carried out 
according to standard procedures with an alkaline phosphatase-conjugated mouse monoclonal anti-6X His 
tag antibody (HIS-1; Abcam, Cambridge, UK).  
 
Autophosphorylation Activity Assay  
 
To assess the autophosphorylation activity of JAK2, the 0.4-μM JAK2 recombinant enzyme was 
incubated in the presence of [γ
32
P]ATP at room temperature with a reaction buffer (25 mM Tris-HCl, pH 8.0, 
0.15 M NaCl, 10 mM MgCl2, 0.5 mM NaF, 0.1 mM Na3VO4, 5% dimethyl sulfoxide, 0.05 μM [γ
32
P]ATP 
[0.25 μCi・μl-1 in the reaction]). The reaction was stopped with the addition of protein loading dye (50 mM 
Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 0.1 M DTT, 0.01% bromophenol blue). The reaction products 
were separated via SDS-PAGE. Polyacrylamide gels were stained with Coomassie Brilliant Blue and used to 
expose a phosphor screen for 30 minutes. Subsequently, the phosphor screen was visualized using an FLA-
7000IR scanner (FujiFilm, Tokyo, Japan) and analyzed using the MultiGauge software program (FujiFilm). 
Radiolabeled protein bands of autophosphorylated JAK2 were excised from the gel and dissolved in a 
mixture of hydrogen peroxide and perchloric acid (2:1 v/v). Čerenkov radiation in the bands was measured 
using a liquid scintillation analyzer (Tri-Carb 2910TR; PerkinElmer, Waltham, Massachusetts, USA), and 
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counts per minute were calculated for each reaction variant using the QuantaSmart (version 3.00) and Tri-
Carb LSC software programs (PerkinElmer). 
 
Peptide Tyrosine Phosphorylation Assay  
 
The catalytic activity of recombinant JAK2 was measured via phosphorylation of the STAT5 peptide 
(TPVLAKAVDGYVKPQIKQVV; synthesized in the Peptide Synthesis Laboratory of the Institute of 
Biochemistry and Biophysics, Polish Academy of Sciences) using a kinase reaction buffer (50 mM Tris-Cl, 
pH 8.0, 0.15 M NaCl, 10 mM MgCl2, 0.5 mM NaF, 0.1 mM Na3VO4, 5% dimethyl sulfoxide, ATP 
[Promega, Madison, Wisconsin, USA], STAT5 peptide and 50 nM JAK2 recombinant kinase 
[preautophosphorylated form]). The concentrations of the substrates (ATP and peptide) varied. The kinase 
activity was measured using an EnzyChrom kinase assay kit (BioAssay Systems, Hayward, California, USA). 
The level of ADP was measured using a coupled reaction of pyruvate kinase converting ADP to ATP and 
pyruvate. The concentration of pyruvate was counted fluorometrically with the excitation and emission 
wavelengths set at 528 nm and 590 nm, respectively. This procedure was carried out according to the 
manufacturer’s instructions (BioAssay Systems). The fluorescent intensity of the reaction mixtures was 
measured in 384-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) using a Synergy HT-I plate 
reader (BioTek, Winooski, Vermont, USA) with standard reading parameters. 
 
Statistical Analysis  
 
Averaged relative fluorescence units corresponding to the JAK2 catalytic activity were plotted 
against a logarithm of the concentration of the CABA derivatives. The data were fit to a dose-response curve 
function according to the equation y = A1 + ([A2-A1]/[1 + 10^(logx0-x)・p]), in which A1 is the bottom 
asymptote, A2 is the top asymptote, logx0 is the center, and p is the Hill slope. The weighting method for the 
fitting was set to instrumental. The 20% inhibitory concentration, IC50, and 80% inhibitory concentration as 
well as the Hill coefficient, a measure of cooperative binding of ligands, were calculated. Statistical 
significance was expressed as the 95% confidence interval (CI) of the fit parameters. 
 
Molecular Docking  
 
Docking was carried out using the AutoDock software program (version 4.2) [28, 29]. The target 
protein was the crystallographic structure of JAK2 with the Protein Data Bank database code 2B7A [30]. The 
target protein was rigid, and the ligands had conformational flexibility. Atomic partial charges were 
computed using the Gasteiger method. Electrostatic, desolvation, and atomic affinity grid maps for each atom 
type were constructed. The cubic grid maps were centered on the JAK2 kinase domain cavity and had 
dimensions of 47 × 47 × 47 Å with 0.375-Å spacing between the grid points. The Lamarckian hybrid 
genetic algorithm was used as the search method for low-energy binding conformations with a modified set 
of parameters. Local search was carried out with standard parameters. A semiempirical free energy force 
field was used to evaluate conformational energies of the ligands in JAK2 [31, 32]. Clustering analysis of 100 
docked conformations was carried out for each ligand. 
 
Geometry Optimization  
 
Complexes of the JAK2 kinase domain with selected pairs of WP1130 generated in the molecular 
docking experiments were optimized via energy minimization and simulated annealing simulations 
performed using Yet Another Scientific Artificial Reality Application. An Amber03 force field was applied 
[33, 34] using the Particle Mesh Ewald algorithm [35] to treat long-range electrostatic interactions with a 
7.86-Å cutoff value. Prior to optimization, virtual titration was performed to set up optimal microscopic 
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protonation states. Structures were solvated with a 0.9% NaCl aqueous solution (pH 8.0) with cell 
neutralization [36]. Solvated structures were subjected to energy minimization using the steepest descent 
method followed by a simulated annealing procedure (time step 2 fs, atom velocities scaled down by 0.9 
every 10th step). 
 
Molecular Dynamics Simulation  
 
The stability of the complexes of the principal conformation clusters of the selected ligands WP1065, 
WP1130, and WP1702 with the JAK2 kinase domain (AutoDock initial states) was tested using molecular 
dynamics (MD) simulations. The same testing was used for complexes of JAK2 and selected pairs of 
WP1130 after careful geometry optimization using Yet Another Scientific Artificial Reality Application. MD 
simulations were performed with a water solution for 5 ns after thermalization and equilibration of the system 
at T = 310 K, atmospheric pressure, and salt concentration of 0.05 in a rectangular cuboid. The NAMD 
library [37], which is capable of carrying out simulations for large molecular systems with scalable parallel 
MD algorithms, was used. This library was developed by the Theoretical and Computational Biophysics 
Group at the Beckman Institute for Advanced Science and Technology at the University of Illinois at Urbana-
Champaign (http://www.ks.uiuc.edu/Research/namd). The CHARMM27 force field [38] and a TIP3P water 
model [39] were applied. Parametrization of the ligands was carried out using the ParamChem interface 
(https://www.paramchem.org) for the CGenFF software program (version 0.9.6) in the CHARMM General 
Force Field (2b7) [40-42]. Energy analysis was performed for stable complexes in MD simulations. The 
interaction energy of the ligand-protein and ligand-ligand pairs was averaged over the MD trajectories. 
 
Multiple Sequence Alignment  
 
Multiple sequence alignment of four human JAK protein sequences—JAK1 (GI: 215274013, 
P23458.2), JAK2 (GI: 12643404, O60674.2), JAK3 (GI: 50403745, P52333.2), and TYK2 (GI: 56405328, 
P29597.3)—was performed using the ClustalX2 software program [43] with a gap opening penalty of 10, 
gap extension penalty of 0.2, and identity matrix. The multiple sequence alignment was then processed and 
visualized using the Geneious 6 software program (Biomatters, San Francisco, California, USA). For 
improved clarity of the alignment, only C-terminal parts of proteins are shown in Fig. (2A). The residues 
were colored according to position conservation: 100%, green; 80-100%, dark yellow; 60-80%, yellow; and 
less than 60%, no color (BLOSUM62 score matrix, threshold set to 4). 
 
CABA Derivatives  
 
Compounds used in this study were synthesized at the laboratories of Waldemar Priebe and Wiesław 
Szeja. Chemical structures of the representative compounds listed below are presented in Fig. (1). 
WP1055: (E)-2-cyano-N-benzyl-3-(pyridin-2-yl)acrylamide 
WP1065: (E)-2-cyano-N-[(S)-1-phenylethyl]-3-(pyridin-2-yl)acrylamide 
WP1174: (E)-2-cyano-N-[(R)-1-phenylethyl]-3-(pyridin-2-yl)acrylamide 
WP1130: (E)-2-cyano-N-[(S)-1-phenylbutyl]-3-(3-bromopyridin-2-yl)acrylamide 
WP1682: (E)-2-cyano-N-[(S)-1-phenylbutyl]-3-(4-bromopyridin-2-yl)acrylamide 
WP1702: (E)-2-cyano-N-[(S)-1,4-diphenylbutyl]-3-(3-bromopyridin-2-yl)acrylamide 
WP1703: (E)-2-cyano-N-[(S)-1,4-diphenylbutyl]-3-(4-bromopyridin-2-yl)acrylamide 
Certain commercially available inhibitors of the JAK2 kinase were included in the study as reference 
compounds: AG490, (E)-2-cyano-N-benzyl-3-(3,4-dihydroxyphenyl) acrylamide (Sigma-Aldrich), 
lestaurtinib (CEP701), and tofacitinib (tasocitinib, CP690550) (LC Laboratories, Woburn, Massachusetts, 
USA).  
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RESULTS  
 
JAK2 Expression and Purification  
 
To optimize the expression of the JAK2 sequence in insect cells, we determined the kinetics using 
Western blot analysis with an anti-histidine antibody. The highest concentration of JAK2 in the lysate 
supernatant was recorded at 24 hours after infection in HF insect cells (Supplementary Fig. 1). Proteolytic 
degradation 48 hours after infection and accumulation of the JAK2 protein in a lysate pellet, which 
contributed to reduced levels of the solubilized form of the recombinant kinase, were the consequences of a 
high instability index for the JAK2 kinase domain (47.84), aliphatic index (83.50), and grand average of 
hydropathicity (-0.553) [44]. Owing to the high instability and relatively high hydrophobicity of the JAK2 
kinase domain, we investigated the influence of several different detergents on the stabilization of 
recombinant JAK2 in an aqueous solution. To rule out influence of the solubilizing properties of the 
glutathione S-transferase protein, we cleaved the JAK2 kinase domain on glutathione-agarose beads via 
thrombin-directed proteolysis. Four detergents—Triton X-100, Thesit, DDM, and Brij 35—clearly 
stabilized the JAK2 kinase domain (Supplementary Fig. 2). Consequently, we used Triton X-100 in all of 
the purification buffers. 
 
Inhibition of JAK2 Autophosphorylation by CABA Analogs  
 
We analyzed the autophosphorylation activity of the recombinant JAK2 kinase via incorporation of 
32
P from γ
32
P[ATP]. Specifically, we examined the kinetics of autophosphorylation for two forms of the 
JAK2 protein: 1) the nonphosphorylated form obtained according to the standard protein purification 
procedure and 2) the form preautophosphorylated during its purification. The mean level (± standard 
deviation) of specific activity of the JAK2 kinase domain was 60.5 ± 1.55 pmol・mg-1・min-1 and 7.2 ± 0.03 
pmol・mg-1・min-1, respectively. However, the calculated kinase activities had only qualitative significance 
because we carried out the autophosphorylation reaction under nonsteady-state conditions with a higher 
concentration of the JAK2 enzyme (acting as an autosubstrate) than of ATP. 
We then assessed the effects of a library of 24 CABA derivatives on the autophosphorylation activity 
of JAK2 at a concentration of 100 μM. This allowed for selection of potential JAK2 inhibitors (Table 1). 
We used a low ATP concentration (0.05 μM) in the autophosphorylation assay to prevent forfeiture of ATP-
competitive JAK2 inhibitors. Five CABA analogs inhibited the JAK2 autophosphorylation activity by about 
50% (WP1055, WP1065, WP1174, WP1702, and WP1703), and two compounds inhibited it by 88% 
(WP1130 and WP1682). These results indicated that these compounds are weak inhibitors of the 
autophosphorylation activity of JAK2. The inhibition levels allowed for estimation of the IC50 of WP1055, 
WP1065, WP1174, WP1702, and WP1703 of about 100 μM under the assumed reaction conditions. Only 
WP1130 and WP1682 had an IC50 below 100 μM in inhibition of the autophosphorylation activity of 
JAK2. 
 
Inhibition of JAK2-Catalyzed Phosphorylation 
 
The peptide used as a reporter reaction substrate was a 20-amino-acid fragment of STAT5 protein 
containing the tyrosine (Tyr694) that can be phosphorylated by JAK2. We performed the reaction under 
steady-state conditions. The Michaelis-Menten constant calculated for STAT5 peptide phosphorylation was 
126.7 ± 24.1 μM. The maximal apparent activity of phosphorylation catalyzed by JAK2 under these 
conditions reached 1.11 ± 0.16 μmol・mg-1・min-1. We have reassessed the potency of the known JAK2 
inhibitors lestaurtinib and tofacitinib, and their respective IC50 values were 64.4 nM and 106.7 nM. In 
addition, inhibition of phosphorylation activity of JAK2 by the commercially available analog AG490 was in 
the micromolar range (IC50 = 30.4 μM) and was in agreement with previously reported data [45]. 
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We then determined the IC50 values and Hill coefficients of inhibition for selected CABA analogs 
(Table 2). We derived the parameters from the dose-response curve regression analysis of the JAK2 activity 
modulated by the inhibitors. Six of the CABA derivatives inhibited the phosphorylation activity of JAK2 at 
an IC50 less than 20 μM. These compounds evidently had greater affinity for the activated JAK2 than for the 
inactive, nonautophosphorylated kinase. Four CABA derivatives—WP1130, WP1682, WP1702, and 
WP1703—had similar IC50s of about 10 μM. In contrast, the inhibitory activity of WP1130 and WP1682 was 
higher than that of WP1702 and WP1703 in an autophosphorylation assay (Table 1). This phenomenon 
may be explained by more than just the higher affinity of WP1702 and WP1703 for the phosphorylated form 
of JAK2. Additionally, the Hill coefficient was much higher for WP1130 and WP1682 than for WP1702 and 
WP1703. A coefficient higher than 1 suggests positive cooperativeness of binding (synergism). 
Consequently, the 80% inhibitory concentration was much smaller for WP1130 and WP1682 (16.9 μM and 
18.5 μM, respectively) than for WP1702 and WP1703 (67.6 μM and 60.1 μM, respectively). The Hill 
coefficients for WP1702 and WP1703 were slightly smaller than 1 (Table 2). 
To assess the inhibition mechanism, we determined the dose-response fit parameters for various 
concentrations of the ATP and peptide substrates (Table 3). We observed slightly different behavior of the 
three inhibitors. The inhibitory activity of WP1065 was statistically invariant in all of the substrate 
concentrations, indicating that WP1065 may be a noncompetitive inhibitor of JAK2. The IC50 of WP1130 
was practically unaffected by ATP and only slightly increased (2.5-fold) at the highest concentration of the 
STAT5 peptide. Notably, a 10-fold increase in ATP concentration decreased the Hill coefficient for WP1130 
from -2.40 to -1.27. In addition, ATP decreased the synergistic behavior of WP1130. This indicated the 
significance of the ATP site to the occurrence of WP1130 cooperativeness. We find highly conceivable that 
at least two molecules of WP1130 bind in the ATP pocket of JAK2. Thus, even though ATP did not cause 
significant elevation of the IC50 for WP1130, this JAK2 inhibitor may be considered bisubstrate-competitive. 
Similarly, the increased ATP and peptide concentrations caused 6.1-fold and 3.3-fold increases, respectively, 
in the IC50 of WP1702. Thus, the competitive behavior of ATP and peptide substrates contributes largely to 
the JAK2-inhibition mechanism of WP1702. We concluded that CABA analogs behave like noncompetitive 
or bisubstrate competitive inhibitors. 
 
Binding Sites for the CABA Analogs in JAK2 
 
We used molecular docking to identify potential sites of binding of CABA analogs to the JAK2 
kinase domain. We performed global search analysis for the following JAK2 inhibitors: WP1055, WP1065, 
WP1174, WP1130, WP1682, WP1702, and WP1703. The plausible binding sites, which are shown in Fig. 
(3) and Supplementary Table 1, include the ATP pocket, activation-loop pocket, α-helix C pocket, and β-
sheet pocket of the N-lobe. Most of these sites are located in the active-site area of JAK2, but the last of these 
pockets is relatively distinct, and binding of JAK2 inhibitors to this area likely plays a minor role in their 
inhibition properties. 
WP1055, WP1065, and WP1174 are structurally similar (Fig. 1), and this similarity is reflected in 
their shared binding patterns (Supplementary Table 1), especially for the WP1065 and WP1174 ligands. We 
found that their binding in the α-helix C pocket had the highest binding energy (-8.23 kcal・mol-1 and -8.48 
kcal・mol-1, respectively) and that they had an optimal hydrogen-bonding network with the amino acids 
Asp894, Arg975, and Lys999, with potency for pi-cation stacking with Lys999. Arg975, which precedes 
catalytic Asp976, is important for stabilization of catalytic residues. Lys999 plays the same stabilization role 
but in reference to the DFG motif. We subjected 10 WP1065-JAK2 initial state complexes corresponding to 
the main clusters resulting from the molecular docking to 5-ns MD simulation. The results confirmed the 
preferable binding mode at the activation loop with a conformation of WP1065 penetrating into the α-helix C 
pocket (Supplementary Fig. 3), with the highest mean (± standard deviation) interaction energy being -54.6 ± 
4.2 kcal・mol-1 (Fig. 3A). A direct consequence of the burial of this conformation deep in the pocket created 
by the activation loop and α-helix C adjacent to the ATP pocket may be an allosteric mode of action of 
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WP1065. This observation would be in tune with our enzymatic study results for WP1065 (Table 3), 
specifically, that neither ATP nor STAT5 peptide affected the WP1065 IC50. 
Docking simulation of WP1130 and WP1682 revealed several distinct poses binding between the 
ATP pocket and activation-loop pocket with similar affinities (Supplementary Table 1). Although the 
WP1130 conformation in the ATP pocket at the hinge loop had the highest binding energy (-8.27 kcal・mol-
1
), it did not form a hydrogen-bonding network. In comparison, the conformations interacting at the interface 
between the ATP pocket and activation-loop pocket and in the activation-loop pocket itself exhibited the 
potential to form hydrogen bonds with the conserved amino acids Lys857, Asn859 (glycine loop), Asp976 
and Asn981 (catalytic loop), and Glu1015 (activation loop). We carried out MD simulations for 20 
WP1130-JAK2 complexes, which indicated two pockets with the most stable poses (Supplementary Fig. 3): 
the activation-loop pocket (-66.4 ± 5.7 kcal・mol-1; Fig. 3C) and the ATP pocket (-62.9 ± 9.2 kcal・mol-1; 
Fig. 3B). The remaining three most stable WP1130 conformations bound in the ATP pocket with interaction 
energies of -53.9 ± 4.3 kcal・mol-1, -52.3 ± 3.4 kcal・mol-1, and -51.9 ± 4.6 kcal・mol-1. The natural 
conclusion is that two distinct WP1130 conformations may interact with the active JAK2 site with similar 
potency: one in the ATP binding site and the other in the peptide-binding site. This suggests multisite binding 
and a bisubstrate-competitive mechanism of action of WP1130. 
WP1702 and WP1703, which have bulky hydrophobic moieties, bind in the ATP pocket with higher 
affinities (EB < -9 kcal・mol-1) than those of WP1130 and WP1682 (Supplementary Table 1). The second 
predominant site of interaction after the ATP pocket was the interface between the ATP pocket and the 
activation-loop pocket. WP1702 and WP1703 may form hydrogen bonds analogous to those formed by 
WP1130 and WP1682. MD simulations of 31 WP1702-JAK2 initial conformations identified the four most 
stable complexes with interaction energies markedly higher than those of the other complexes 
(Supplementary Fig. 3): -81.3 ± 6.0 kcal・mol-1 (Fig. 3D), -80.3 ± 10.4 kcal・mol-1 (Fig. 3E), -74.3 ± 4.1 
kcal・mol-1, and -70.7 ± 4.5 kcal・mol-1 (Fig. 3F). The first complex binds at the activation loop and 
penetrates into the ATP pocket; it may disrupt other less stable conformations with the potential to bind in the 
ATP pocket (the next two conformations) as well as the activation-loop pocket (the fourth conformation). 
Also, the first most stable conformation may counteract proper binding of both ATP and phosphorylated 
peptide. Similarly, concentrations of these two substrates influence the IC50 of WP1702 (Table 3). 
The optimal locations of the CABA derivatives in the active site of JAK2, depicted in Fig. (4), reflect 
the deepest and widest cleft of the JAK2 kinase domain, extending from the hinge loop (ATP pocket) to the 
α-helix C (α-helix C pocket). Binding of the high-energy conformations in the regions directly involved in 
binding of the ATP and peptide substrates (observed for WP1130 and WP1702) implies a competitive 
mechanism of JAK2 inhibition. Stable interaction of a conformation deep in the α-helix C pocket (observed 
for WP1065) demonstrates an allosteric mechanism of JAK2 inhibition. We selected the following 
conformations for schematic representation in Fig. (4) based on the mean interaction energies determined in 
the MD simulations: WP1065, conformation 1; WP1130, conformations 1, 19, 20, 26, and 50; and WP1702, 
conformations 1, 2, 3, and 12 (see Supplementary Fig. 3 for an illustration of the statistics regarding the 
interaction energies). 
 
Structural Interpretation of the Synergistic Binding Mechanism of WP1130 
 
Our enzymatic results (Table 3) demonstrated that ATP has a strong impact on the Hill coefficient of 
WP1130: the higher the ATP concentration, the lower the coefficient. Thus, ATP abrogates the synergistic 
interaction of WP1130 with the active site of JAK2. To gain insight into the cooperative mechanism of 
binding of WP1130 to JAK2, we combined one of the two distinct high-energy conformations of WP1130 in 
the ATP-binding site with one of the seven other conformations. The selected poses included not only those 
with the highest binding energy but also others to keep the group structurally diverse. We carefully optimized 
the geometry of 14 such co-structures consisting of two molecules of WP1130 in the active JAK2 site. We 
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subjected the resulting complexes to 5-ns MD simulations. The energetic advantage of the binding of two 
ligand molecules in the active site of the JAK2 kinase domain over the binding of one ligand molecule was 
expressed as follows: ΔEA(P) + ΔEB(P) + EAB, in which ΔEA(P) is the change in interaction energy between 
the protein environment and ligand A, ΔEB(P) is the change in interaction energy between the protein 
environment and ligand B, and EAB is the interaction energy between ligands A and B. The total energetic 
gain for the ligand pairs is shown in Fig. (5). The interaction energy increased for 7 of the 14 co-structures, 
but we saw a positive influence of all three factors (ΔEA(P), ΔEB(P), and EAB) for only three of them: 2 & 35 (-
63.1 kcal・mol-1), 2 & 38 (-45.2 kcal・mol-1), and 2 & 42 (-44.1 kcal・mol-1). In general, interaction 
between two ligand molecules had a positive impact on the binding of the given pair, and this energy may 
have exceeded -10 kcal・mol-1 (pair 1 & 26). However, only a change in the interaction energy with amino 
acids of the protein environment is decisive. The co-structure with the highest energetic gain, 2 & 35, which 
is depicted in Fig. (4), was only minimally influenced by EAB but was greatly influenced by ΔEA(P) and 
ΔEB(P). These results suggested that synergistic binding of WP1130 results from induced fit transformation of 
protein cavities in the active JAK2 site upon binding of at least two molecules of WP1130. Regardless of the 
exact molecular mechanism of the positive cooperativeness of WP1130, our results demonstrated that 
binding two WP1130 ligand molecules in the active JAK2 site is structurally possible and may be 
energetically favorable. Why this synergism is possible for WP1130 (and WP1682) but not other structurally 
close CABA analogs is unclear and requires further investigation. For ligands with bulky moieties such as 
WP1702 and WP1703, the natural cause of lack of synergism may result from steric hindrances. This could 
explain the slightly lower Hill coefficients for these two ligands than for WP1130 and WP1682. 
 
 
DISCUSSION  
 
The inhibitors of the JAK2/STAT3 and JAK2/STAT5 signaling pathways described herein are 
derivatives of natural compounds structurally related to CABA. Analysis of molecular targets for these 
inhibitors is crucial to understanding their precise mechanisms of action and designing more effective 
inhibitors of these pathways. Furthermore, identification of their binding sites and specific interactions may 
be important for future design of high affinity JAK2 inhibitors with specific non-ATP-competitive modes of 
action. Thus, we studied interactions of selected CABA analogs with JAK2 kinase and identified and 
characterized structural fragments of the CABA scaffold important for JAK2 inhibition and binding. 
The CABA derivatives WP1065, WP1174, WP1130, WP1682, WP1702, and WP1703 exhibited 
affinity for the JAK2 kinase domain at low micromolar IC50 values ranging from 2.9 to 22.1 that are 
indicative of only weak inhibition of JAK2. Currently used inhibitors of JAK2 kinase activity have IC50 
values in the low nanomolar range (e.g., TG101348 [47], lestaurtinib [48], tofacitinib [49]). However, a 
potential disadvantage of these inhibitors is their ATP competitiveness, limiting their biological selectivity 
because of high conservation of ATP binding pockets and concurrent inhibition of multiple kinases. In 
summary, non-ATP-competitive kinase inhibitors with biologically relevant potency may complement 
existing ATP-competitive inhibitors by offering increased selectivity and ability to overcome de novo and 
acquired resistance to ATP-competitive inhibitors [50, 51]. 
Our results suggested that CABA analogs with the highest affinity for JAK2 behave like allosteric 
noncompetitive (WP1065) or bisubstrate-competitive (WP1130 and WP1702) inhibitors of JAK2. WP1065 
preferentially binds in the α-helix C pocket at the N-terminal portion of the activation loop. Competitive 
binding of WP1065 at the ATP site or peptide substrate site does not seem probable. Rather, allosteric 
binding of WP1065 conceivably influences the amino acid environment crucial for proper orientation of 
the substrate-interacting and catalytic amino acids. Interestingly, WP1065 with an allosteric mechanism of 
action inhibits the growth of glioma cells [21] and JAK2 enzymatic activity at similar drug concentrations 
(about 25 μM). On the other hand, both WP1130 and WP1702 seem to interact with JAK2 in two regions: the 
ATP pocket and peptide substrate site. We propose that the mechanism responsible for the potential positive 
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cooperativeness of WP1130 may be the binding of two ligand molecules in the active-site area of JAK2. The 
diversity in inhibition is a result of subtle structural differences in the inhibitors. 
The α-helix C and activation loop regions have relatively little sequence conservation and are 
characteristic for specific kinase families. Moreover, the amino acids in these two regions can distinguish the 
JAK subfamilies JAK1, JAK2, JAK3, and TYK2. Among amino acids of JAK2 making contact with 
WP1065, the only nearly invariant residues in the protein kinase superfamily are Arg975, Gly996, and 
Leu997 [52]. Four additional residues in the human JAK family are invariant: Phe860, Glu898, Ile901, and 
Lys999 (Fig. 2A). The pattern of the remaining amino acids (Asp894, Arg897, Thr998, Lys1011, Pro1013, 
and Gly1014) is unique to particular kinases and may contribute to the selective affinity of ligands for the 
JAK2 kinase domain. An additional advantage of the inhibitor WP1065 is the relatively high value of the 
ligand efficiency parameter (0.32). Therefore, allosteric interaction of WP1065 beyond the ATP catalytic site 
may provide the basis for the design of noncompetitive CABA inhibitors that selectively inhibit the activity 
of not only JAK family but also subfamily members. 
Our conclusion is further supported by studies of allosteric noncompetitive inhibitors of the activity 
of both serine/tyrosine mitogen-activated protein kinase (MEK) 1 and 2 (PD184352, PD318088, and 
PD334581) [53, 54, 55]. Identified by our group, the WP1065 binding site is also designated the MEK 
pocket, which may be used to synthesize novel type III noncanonical kinase inhibitors [56, 57]. In light of 
these results, we find highly conceivable that the JAK2 kinase inhibitor WP1065 acts in an analogous manner 
to the allosteric MEK1 and MEK2 inhibitors. These assumptions should be investigated further. 
The in vitro anticancer activity of the studied CABA analogs compares very favorably with the 
activities reported for many natural derivatives of cinnamic acid, such as caffeic acid (3,4-dihydroxycinnamic 
acid) and its esters. These compounds have attracted much attention owing to their ability to inhibit the 
growth of neoplastic cells via multiple mechanisms: antioxidant potential, induction of apoptosis, suppression 
of metastasis, cell-cycle arrest, and immunomodulation [58-61]. Caffeic acid phenethyl ester is one of the 
most studied CABA analogs. It specifically suppresses activation of the nuclear transcription factor NF-κB 
and matrix metalloproteinases (MMP-2 and MMP-9) as well as phosphorylation of AKT kinase (Ak 
thymoma) and focal adhesion kinase. Importantly, many natural polyphenols, including caffeic acid and its 
derivatives, are reported to act as micromolar inhibitors of protein kinases [62, 63]. The present study 
confirmed that our selected CABA analogs also directly inhibit JAK2 protein kinase. This demonstrates that 
further exploration of our findings may lead to the design of therapeutically effective compounds. 
 
 
CONCLUSIONS  
 
CABA analogs appeared to be mechanistically diverse inhibitors. We identified 6 of 24 tested compounds as 
weak inhibitors of phosphorylated (activated) JAK2 with micromolar affinity (IC50s ranging from 2.9 to 22.1 
μM). The JAK2 inhibition and mode of JAK2 binding can be altered by small structural changes and can be 
either an allosteric noncompetitive (WP1065) or bisubstrate-competitive (WP1130 and WP1702). Our results 
indicated that direct inhibition of JAK2 enzymatic activity by the CABA derivatives WP1065, WP1130, and 
WP1702 potentially contributes, albeit minimally, to overall suppression of the JAK2/STAT5 signaling 
pathway in cancer cells. This study offers a background for the design of novel non-ATP-competitive JAK2 
inhibitors with increased selectivity and ability to overcome de novo and acquired resistance to existing 
inhibitors. 
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Table 1. Inhibition of the autophosphorylation activity of the JAK2 kinase by selected CABA 
derivatives. 
 
CABA derivative 
mean JAK2 activity ± standard 
deviation (pmol·mg
-1
·min
-1
) 
Control 74.3 ± 8.6 
WP1055 41.2 ± 6.6 
WP1065 36.8 ± 3.5 
WP1174 33.6 ± 5.5 
WP1086 51.2 ± 6.7 
WP1130 8.5 ± 0.8 
WP1682 8.9 ± 2.3 
WP1702 32.8 ± 6.0 
WP1703 33.8 ± 0.8 
 
 
 
 
Table 2. The effects of selected CABA derivatives on JAK2-catalyzed STAT5 peptide 
phosphorylation. 
 
CABA derivative 
dose-response fit parameter* 
IC50, M (95% CI) -Hill coefficient (95% CI) 
WP1130 9.5 (8.8-10.2) 2.40 (2.80-2.01) 
WP1682 10.3 (6.5-16.3) 2.34 (3.37-1.30) 
WP1702 9.6 (5.8-15.8) 0.71 (0.94-0.47) 
WP1703 9.3 (6.7-12.9) 0.76 (0.86-0.65) 
WP1065 19.9 (16.0-24.7) 0.97 (1.08-0.87) 
WP1174 18.5 (15.6-22.0) 1.07 (1.18-0.96) 
WP1055 43.6 (25.5-74.7) 1.01 (1.43-0.60) 
*Concentration of the substrates in the reaction: 25 μM ATP and 300 μM STAT5. 
 
 
 
 
Table 3. Inhibition parameters (IC50 and Hill coefficient) for three CABA derivatives as determined in 
two sets of substrate (ATP and STAT5 peptide) concentrations. 
 
CABA 
derivative 
dose-response fit parameter 
25 M ATP and 25 M STAT5 300 M ATP and 25 M STAT5 
IC50, M (95% CI) 
-Hill coefficient 
(95% CI) 
Ligand 
efficiency* 
IC50, M (95% CI) 
-Hill coefficient 
(95% CI) 
WP1065 14.8 (7.9-27.5) 0.96 (1.27-0.67) 0.32 22.1 (13.9-35.0) 1.00 (1.38-0.62) 
WP1130 3.8 (3.5-4.2) 2.09 (2.33-1.85) 0.32 6.2 (5.0-7.8) 1.27 (1.59-0.96) 
WP1702 2.9 (2.1-3.9) 0.91 (1.04-0.78) 0.26 17.3 (12.1-24.8) 1.16 (1.53-0.78) 
*Ligand efficiency was calculated according to the equation: 1.4・(-logIC50)/N, N is the number of non-
hydrogen atoms [46]. 
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Fig. (1). Representative structures of the analogs of cinnamic acid benzyl amide used in this study. 
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Fig. (2). Structure of the JAK2 kinase domain with its conserved elements. A) Multiple sequence 
alignment of the human JAK kinase family—JAK1, JAK2, JAK3, and TYK2—with the features of the active 
site marked. The hinge loop encompasses amino acids 929-935 (MEYLPYG), the glycine loop encompasses 
amino acids 856-861 (GKGNFG), the protein tyrosine kinase active-site signature (catalytic loop) 
encompasses amino acids 972-984 (YIHRDLATRNILV), and the activation loop encompasses amino acids 
994-1023 (with both the DFG triplet 994-996 and autophosphorylated Y1007/Y1008). B) Binding sites of the 
CABA derivatives on the JAK2 kinase domain surface as determined via molecular docking. Four regions in 
the vicinity of crucial structural elements were detected: the ATP pocket, activation-loop pocket, α-helix C 
pocket, and β-sheet pocket of the N-lobe. The first two regions are located in the active site of the JAK2 
kinase domain and form large binding cavity. The third region neighbors the active site. The fourth 
region is quite distant from the active JAK2 site. 
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Fig. (3). High-energy poses of the representative CABA ligands WP1065, WP1130, and WP1702. A) 
WP1065 was buried deep in the α-helix C pocket at the activation loop and at the α-helix C. B) and C) 
WP1130 bound in two regions with similar affinity: the ATP pocket (B) and activation-loop pocket (C). D-F) 
WP1702 also bound with similar affinity in the ATP pocket (F) and activation-loop pocket (E) as well as at 
the interface between these two cavities (D). The vertical line separates the active site of JAK2: the left side 
contains the ATP-pocket region, and the right side contains the activation loop engaged in peptide 
substrate recognition. 
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Fig. (4). The most optimal locations of the CABA derivatives in the JAK2 catalytic domain. The 
following conformations were selected for comparison of their binding poses based on their mean interaction 
energies as determined in MD simulations: WP1065, conformation 1; WP1130, conformations 1, 19, 20, 26, 
and 50; WP1702, conformations 1, 2, 3, and 12 (see Supplementary Fig. 3 for an illustration of the statistics 
of the interaction energies). The different colors correspond to magnitudes of the interaction energies: -54.6 
kcal・mol-1 (red) to -11.3 kcal・mol-1 (blue) for WP1065, -66.4 kcal・mol-1 (red) to -7.3 kcal・mol-1 (blue) 
for WP1130, and -81.3 kcal・mol-1 (red) to -24.0 kcal・mol-1 (blue) for WP1702. 
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Fig. (5). Change in the interaction energy of WP1130 as a result of synergistic binding of two molecules 
of this ligand in the active center of JAK2. Energetic gain by binding of two WP1130 molecules was 
expressed as ΔEA(P) + ΔEB(P) + EAB, in which ΔEA(P) is the change in interaction energy between the protein 
environment and ligand A, ΔEB(P) is the change in interaction energy between the protein environment and 
ligand B, and EAB is the interaction energy between ligands A and B. The most stable co-structure of two 
WP1130 molecules in the active site of JAK2 (pair 2 & 35) is shown below the graph. 
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SUPPORTIVE/SUPPLEMENTARY MATERIAL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. (1). Purification of the recombinant JAK2 kinase domain. Western blot 
analysis of the kinetics of expression of the recombinant JAK2 kinase domain with N-terminal GST, S 
and hexahistidine tags (molecular weight, 70 kDa) in insect cell lysates with an anti-HIS antibody 
(Abcam). Membrane lanes 1-5 correspond to the lysate supernatants, and lanes 6-10 correspond to the 
lysate pellets. M, protein marker (numbers are molecular weights in kDa); lanes 1 and 6, 0 hours after 
infection; lanes 2 and 7, 24 hours after infection; lanes 3 and 8, 48 hours after infection; lanes 4 and 9, 
72 hours after infection; and lanes 5 and 10, 96 hours after infection. The highest level of expression of 
the soluble form of the recombinant kinase was observed at 24 hours after infection (band migration at 
70 kDa). Forty-eight hours after infection and later, the full-length recombinant protein both was 
proteolyzed and accumulated in pellets in an insoluble form.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Fig. (2). The stability of the JAK2 kinase domain in buffers containing 0.1% 
detergents: lane 1, control without a detergent; lane 2, Triton X-100; lane 3, CHAPS; lane 4, Thesit; 
lane 5, Tween-20; lane 6, DDM; and lane 7, Brij 35. The concentration of the soluble form of the JAK2 
kinase domain was analyzed using SDS-PAGE after thrombin-directed proteolysis of the fusion protein 
and release of it from glutathione-agarose beads. The JAK2 kinase domain was visibly stabilized in 
solution by four detergents: Triton X-100, Thesit, DDM, and Brij 35. 
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Supplementary Table 1. Binding regions of CABA derivatives in the JAK2 kinase domain 
identified in molecular docking simulations.* 
 
 
inhibitor 
region of binding 
ATP pocket 
interface between ATP and activation loop 
pocket 
activation loop 
pocket
helix C 
pocket
sheet pocket 
of the N-lobe 
WP1055 
-EB  6.98 - 6.90 7.72 7.26 
HB Leu932 (6.91) - Glu1015 (0.18) 
Arg975 (4.71) 
Asp894 (2.23) 
Lys999 (0.05) 
Gln906 (3.45) 
Tyr913 (4.42) 
Tyr913 (5.20) 
WP1065 
-EB 7.00 6.74 7.03 8.23 7.18 
HB - 
Asn859 (4.89) 
Asp976 (2.99) 
Glu1015 (6.56) 
Arg975 (5.00) 
Asp894 (2.68) 
Lys999 (0.17) 
Tyr913 (7.46) 
WP1174 
-EB 7.47 7.00 7.07 8.48 7.60 
HB 
Tyr931 (1.92) 
Leu932 (3.25) 
Arg980 (5.14) 
Asn981 (0.19) 
Glu1015 (2.93) 
Arg975 (5.10) 
Asp894 (2.50) 
Lys999 (0.05) 
Tyr913 (3.24) 
Tyr913 (6.36) 
WP1130 
-EB 8.27 7.61 7.51 7.77 7.75 7.22 7.17 
HB - 
Asn859 (4.25) 
Asp976 (0.58) 
Lys857 (5.00) 
Asn981 (3.63) 
Asn981 (0.56) 
Asn981 (1.83) 
Glu1015 (2.09) Arg975 (4.79) 
Gln906 (4.93) 
Tyr913 (0.16) 
WP1682 
-EB 7.90 7.34 7.15 6.98 7.63 7.04 - 
HB - Asn859 (6.20) 
Asn859 (4.46) 
Arg980 (4.48) 
Asn859 (4.63) 
Asn981 (5.94) 
Glu1015 (5.63) Arg975 (3.39) - 
WP1702 
-EB 9.07 9.61 9.31 8.56 - 
HB - 
Asn859 (4.20) 
Asp976 (2.72) 
Glu1015 (7.78) - - 
WP1703 
-EB 9.33 9.42 8.39 8.60 8.76 8.31 - 
HB - 
Asn859 (6.28) 
Asp976 (2.90) 
Asn859 (3.83) 
Arg980 (3.11) 
Asn859 (4.64) 
Asn981 (4.74) 
Glu1015 (6.74) Lys999 (2.77) - 
 
*The binding energy of poses (EB, kcal·mol
-1) as well as hydrogen bonding (HB) to JAK2 amino acids 
(with indicated energies in kcal·mol-1) were computed using the AutoDock software program (version 
4.2). 
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Supplementary Fig. (3). 
Mean interaction energies 
(with standard deviations) 
for the CABA derivatives  
WP1065, WP1130, and 
WP1702 and the protein 
environment (kcal·mol-1) 
after 5-ns molecular 
dynamics simulation of the 
complexes CABA-JAK2. The 
conformation numbers 
correspond to the initial ligand 
states that resulted from 
molecular docking. Double 
color of a column indicates 
that this particular 
conformation locates in the 
interface between two pockets 
and thus may sterically block 
binding of other conformations 
in both pockets. 
